June 27, 2025

Gout and Ultrasound Predict Carotid Risk

Ultrasound features and gout flares help identify patients at risk for carotid plaque vulnerability, a key factor in stroke risk.

Conexiant

June 26, 2025

MRI Finds Hidden Arthritis After Cancer Therapy

A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.

Conexiant

June 25, 2025

Top Physical Therapies for Knee OA

A large-scale analysis of physical therapies for knee osteoarthritis found knee bracing, hydrotherapy, and exercise to be the most effective options for reducing pain and improving function.

Conexiant

June 24, 2025

Dermatologists Show Lowest Turnover Intent of All Specialists

AMA data show only 19.9% of dermatologists plan to leave their current positions, compared with 40.6% of anesthesiologists.

Conexiant

June 24, 2025

Do CBC Ratios Predict RA Mortality?

Elevated SIRI, NLR, and MLR from routine blood counts independently predicted higher all-cause mortality among patients with rheumatoid arthritis.

Conexiant

June 23, 2025

Sitting-Rising Test Predicts Long-Term Mortality Risk

A 12-year study of over 4,000 adults found that poor performance on a basic sitting and rising test was strongly linked to increased risk of death from natural and cardiovascular causes.

Conexiant

June 23, 2025

Psoriasis Biologics May Reduce Heart Risks

A large international study found that psoriasis patients treated with biologic therapies had a significantly lower risk of cardiovascular disease compared to those receiving oral treatments.

Conexiant

June 23, 2025

Chronic Pain Persists After Joint Replacement Surgery

Roughly 1 in 5 knee replacement patients still experience joint pain after three months, according to a large analysis of nearly 600,000 surgeries.

Conexiant

June 23, 2025

Methotrexate Adds No Psoriasis Benefit to Adalimumab

The addition of methotrexate to adalimumab for the treatment of plaque psoriasis may not improve drug survival, efficacy, or safety compared with adalimumab alone, according to a large real-world cohort study.

Conexiant